載入...
73 Changes in Palivizumab usage in Canada 2005–2017 (Data from CARESS registry)
BACKGROUND: Palivizumabis a monoclonal antibody for preventionof serious lower respiratory tract infection caused by respiratory syncytial virus (RSV) in high risk children. Safety and efficacy were established in infants with bronchopulmonary dysplasia (BPD), prematurity (≤ 35 weeks gestational age...
Na minha lista:
| 發表在: | Paediatr Child Health |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Oxford University Press
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6543311/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/pch/pxz066.072 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|